DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice

INTRODUCTION: The fluoropyrimidines (FP) (5-Fluorouracil, capecitabine, and tegafur) are commonly used anti-cancer drugs, but lead to moderate to severe toxicity in about 10–40% of patients. DPD testing [either the enzyme activity of dihydropyrimidine dehydrogenase (DPD) or the DPYD genotype] identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Martens, Forike K., Huntjens, Daan W., Rigter, Tessel, Bartels, Meike, Bet, Pierre M., Cornel, Martina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997151/
https://www.ncbi.nlm.nih.gov/pubmed/32047438
http://dx.doi.org/10.3389/fphar.2019.01609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997151/
https://www.ncbi.nlm.nih.gov/pubmed/32047438
http://dx.doi.org/10.3389/fphar.2019.01609

Ejemplares similares